Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SPECTRUM PHARMACEUTICALS, INC.

(SPPI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Spectrum Pharmaceuticals Announces Presentation of Poziotinib in Combination with KRASG12C Inhibitors at the 2021 AACR-NCI-EORTC Conference

10/07/2021 | 09:00am EST

Spectrum Pharmaceuticals announced the presentation of preclinical data demonstrating the synergistic impact of poziotinib when combined with KRAS inhibitors in KRASG12C mutant specific cell lines. Jacqulyne Robichaux, Ph.D., Assistant Professor, University of Texas, MD Anderson Cancer Center is presenting a poster titled Pan-ErbB inhibition enhances activity of KRASG12C inhibitors in preclinical models of KRASG12C mutant cancers at the Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10. The conference is hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC). The preclinical data demonstrated that inhibition of EGFR, HER2, HER3, and HER4 signaling by the pan-ErbB inhibitor poziotinib was synergistic when combined with KRASG12C inhibitors. These results highlight the importance of HER3 and HER4 signaling, in addition to EGFR and HER2, after KRASG12C inhibition.


ę S&P Capital IQ 2021
All news about SPECTRUM PHARMACEUTICALS, INC.
12/06SPECTRUM PHARMACEUTICALS : Current Corporate Presentation
PU
12/06Spectrum Pharmaceuticals Submits New Drug Application for Poziotinib to US Food and Dru..
MT
12/06Spectrum Pharmaceuticals Submits New Drug Application for Poziotinib
BU
12/03SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
AQ
12/01Spectrum Pharmaceuticals CEO Agrees to Retire, COO Named Successor From Dec. 31
MT
12/01Spectrum Pharmaceuticals Announces Changes to Management Team and Board of Directors
BU
12/01Spectrum Pharmaceuticals, Inc. Announces Appointment of Tom Riga as President and CEO, ..
CI
12/01Spectrum Pharmaceuticals, Inc. Announces Changes to Board of Directors
CI
11/30Spectrum Pharmaceuticals to Participate in JMP Securities Hematology and Oncology Summi..
BU
11/11Spectrum Pharmaceuticals to Participate in 2021 Jefferies London Healthcare Conference
BU
More news
Analyst Recommendations on SPECTRUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -152 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,57x
Yield 2021 -
Capitalization 244 M 244 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 7,59x
Nbr of Employees 176
Free-Float 98,5%
Chart SPECTRUM PHARMACEUTICALS, INC.
Duration : Period :
Spectrum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPECTRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 1,53 $
Average target price 5,75 $
Spread / Average Target 276%
EPS Revisions
Managers and Directors
Joseph W. Turgeon President, Chief Executive Officer & Director
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
William L. Ashton Chairman
Francois Lebel Chief Medical Officer
Lyndah K. Dreiling Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
SPECTRUM PHARMACEUTICALS, INC.-59.53%244
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888